Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology

Volumn 127, Issue 3, 2012, Pages 495-501

  Stehman, Frederick B ^a   Brady, Mark F ^b   Thigpen, J Tate ^c   Rossi, Emma C ^a   Burger, Robert A ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

Cytokines; Erythropoietin; Ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; HEMOGLOBIN; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; DEATH; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATINICS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84868561933     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.09.002     Document Type: Conference Paper

References (25)

1. American Cancer Society Cancer facts & figures 2011 2011 American Cancer Society Atlanta http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-029771.pdf
2. J. Seidenfeld, M. Piper, C. Flamm, V. Hasselblad, J.O. Armitage, and C.L. Bennett Epoetin treatment of anemia associated with cancer therapy; a systematic review and meta-analysis of controlled clinical trials J Natl Cancer Inst 93 2001 1204 1214
3. P.M. Wilkinson, M. Antonopoulos, M. Lahousen, M. Lind, P. Kosmidis EPO-INT-45 Study Group Epoetin alfa in platinum treated ovarian cancer patients: results of a multinational, multicenter, randomized trial Br J Cancer 94 2006 947 954
4. S. Swift, A.R. Ellison, P. Kassner, I. McCaffery, J. Rossi, and A.M. Sinclair Absence of functional EPOR expression in human tumor cell lines Blood 115 2010 4254 4263
5. A.M. Sinclair, A. Coxon, I. McCaddery, S. Kaufman, K. Paweletz, and L. Liu Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells Blood 115 2010 4264 4272
6. R. Rocconi, B. Long, P. Sullivan, B. Long, M. Blaize, and J. Brown Treatment of chemotherapy-induced anemia in patients with ovarian cancer: does the use of erythropoiesis-stimulating agents worsen survival? Int J Gynecol Cancer 22 2012 786 791
7. R.A. Burger, M.W. Sill, and B.J. Monk Greer Be, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171
8. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
9. S.J. Pocock, and R. Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1975 103 115
10. D.R. Cox The analysis of binary data 1970 Methuen London
11. J.D. Wright, A.I. Neugut, T. Wilde, D.L. Buono, J. Malin, and W.Y. Tsai Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer J Clin Oncol 29 2011 3408 3418
12. U. Dafni Landmark analysis at the 25-year landmark point Circ Cardiovasc Qual Outcomes 4 2011 363 371
13. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719
14. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
15. G.J. Rustin, M. Marples, A.E. Nelstrop, M. Mahmoudi, and T. Meyer Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels J Clin Oncol 9 2001 4054 4057
16. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Amer Stat Assoc 53 1958 457 481
17. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
18. D.R. Cox Regression models and life tables (with discussion) J Roy Stat Soc B 74 1972 187 220
19. Common terminology criteria for adverse events (CTCAE) v3.0 http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm#ctc-30 2006 [Accessed at]
20. T. Wun, L. Law, D. Harvey, B. Sieracki, S.A. Scudder, and J.K. Ryu Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation and erythropoietin Cancer 98 2003 1514 1520
21. G. Thomas, S. Ali, F.J. Hoebers, K.M. Darcy, W.H. Rodgers, and M. Patel Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving radiation and cisplatin for cervical cancer Gynecol Oncol 108 2008 317 325
22. US Food and Drug Administration FDA drug safety communication: erythropoiesis-stimulating agents (ESAs) - Procrit®, Epogen®, and Aranesp® http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/ 103234s5199lbl.pdf
23. J.U. Blohmer, S. Paekpe, J. Sehouli, D. Boehmer, M. Kolben, and F. Würschmidt Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study J Clin Oncol 29 2011 3791 3797
24. J. Bohlius, K. Schmidlin, C. Brillant, G. Schwarzer, S. Trelle, and J. Seidenfeld Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials Lancet 373 2009 1532 1542
25. L.A. Cantrell, S.N. Westin, and L. Van Le The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival Cancer 117 2011 122 126